Search results
The research in my laboratory focuses on the development of new gene therapy approaches…. · Expérience : INSERM · Formation : Université d'Evry-Val d'Essonne · Lieu : Paris et périphérie · 500 relations ou plus sur LinkedIn. Consultez le profil de Mario Amendola sur LinkedIn, une communauté professionnelle d’un milliard de membres.
- INSERM
Mario Amendola. Contact Join us Personal data protection policy. Genethon is a member of the Biotherapies Institute for Rare Diseases that was created by AFM-Telethon.
Mario Amendola; An amendment to this paper has been published and can be accessed via a link at the top of the paper. View. Ex vivo editing of human hematopoietic stem cells for erythroid ...
Mario Amendola 1 2 , Aurélie Bedel 3 4 5 , Ana Buj-Bello 1 2 , Mathieu Carrara 6 , Jean-Paul Concordet 6 , Giacomo Frati 7 8 , David Gilot 9 , Carine Giovannangeli 6 , Alejandra Gutierrez-Guerrero 10 , Marine Laurent 1 2 , Annarita Miccio 7 8 , François Moreau-Gaudry 3 4 5 , Célia Sourd 1 2 , Julien Valton 11 , Els Verhoeyen 10 12
Mario AMENDOLA, PhD 1 CURRICULUM VITAE (updated 2023) PERSONAL DATA Name: Mario Amendola Nationality: Italian E-mail: mamendola@genethon.fr WORKING EXPERIENCE Nov 2022-pres Associate Professor of Molecular Biology, University of Foggia, Italy Dec 2016-pres Chargé de Recherche de 1ère classe (CR1) INSERM, UMR_S951, Evry, FR.
Specifically, by inserting transgenes under the control of the endogenous α or β-globin promoter, we aim to redirect a fraction of the striking globin synthesis capacity of erythroid cells (~7.2gr/day) for therapeutic protein expression without interfering with physiological erythropoiesis. The combination of robust transcription and the ...
Mario Amendola created his "Therapeutic Genome Editing" team within Integrare with funding from Atige
